Study Reveals Increased Cannabis Use in Individuals with Depression

The prevalence of cannabis, or marijuana, use in the United States increased from 2005 to 2017 among persons with and without depression and was approximately twice as common among those with depression in 2017. The findings, which are published in Addiction, come from a survey-based study of 728,691 persons aged 12 years or older.

“Perception of great risk associated with regular cannabis use was significantly lower among those with depression in 2017, compared with those without depression, and from 2005 to 2017 the perception of risk declined more rapidly among those with depression. At the same time, the rate of increase in cannabis use has increased more rapidly among those with depression,” said corresponding author Renee Goodwin, PhD, MPH, of Columbia University and The City University of New York.

The prevalence of past 30-day cannabis use among those with depression who perceived no risk associated with regular cannabis use was much higher than that among those who perceived significant risk associated with use (38.6% versus 1.6%, respectively). 

Certain groups appeared more vulnerable to use. For instance, nearly one third of young adults (29.7%) aged 18–25 with depression reported past 30-day use.

In 2017, the prevalence of past month cannabis use was 18.9% among those with depression and 8.7% among those without depression. Daily cannabis use was common among 6.7% of those with depression and among 2.9% of those without.

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/add.14883

About Journal 

Addiction’s aims are:

• to provide an effective outlet for high quality research in the field of addiction by selecting excellent papers for publication and improving them through the review process,
• to stimulate debate with the field of addiction on matters relating to the science or its translation into clinical practice or policy
• to promote high quality research in the field of addiction worldwide through its publishing and other activities.

Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company’s website can be accessed at www.wiley.com.